Patents Assigned to Spiber Technologies AB
  • Publication number: 20200283487
    Abstract: The present invention provides a fusion protein comprising: i) a solubility-enhancing moiety which is derived from the N-terminal (NT) fragment of a spider silk protein; and ii) a C-type lectin polypeptide. The present invention also provides a truncated SP-A polypeptide which lacks the N-terminal domain of full SP-A and is capable of trimerisation, and to the use of such a truncated SP-A polypeptide in treating or preventing a disease.
    Type: Application
    Filed: December 21, 2016
    Publication date: September 10, 2020
    Applicants: University of Southampton, Spiber Technologies AB
    Inventors: Howard William Clark, Alastair Samuel Watson, Jens Madsen, Jan Johansson, Anna Rising, Nina Kronqvist, Kerstin Nordling
  • Publication number: 20190322710
    Abstract: A recombinant fusion protein is comprising a spider silk fragment and a cyclic RGD cell-binding motif with selectivity for integrins, such as for ?5?1 integrins. The fusion protein is useful as a cell scaffold material and for the cultivation of cells displaying integrins on their cell surface.
    Type: Application
    Filed: May 6, 2019
    Publication date: October 24, 2019
    Applicant: Spiber Technologies AB
    Inventor: My Hedhammar
  • Publication number: 20180170977
    Abstract: A recombinant fusion protein is comprising a spider silk fragment and a cyclic RGD cell-binding motif with selectivity for integrins, such as for ?5?1 integrins. The fusion protein is useful as a cell scaffold material and for the cultivation of cells displaying integrins on their cell surface.
    Type: Application
    Filed: June 23, 2016
    Publication date: June 21, 2018
    Applicant: Spiber Technologies AB
    Inventor: My Hedhammar
  • Patent number: 8729235
    Abstract: The invention provides an isolated major ampullate spidroin protein, which consists of from 150 to 420 amino acid residues and is defined by the formula REP-CT. REP is a repetitive, N-terminally derived protein fragment having from 80 to 300 amino acid residues. CT is a C-terminally derived protein fragment having from 70 to 120 amino acid residues. The invention further provides an isolated fusion protein consisting of a first protein fragment, which is a major ampullate spidroin protein, and a second protein fragment comprising a fusion partner and a cleavage agent recognition site. The first protein fragment is coupled via said cleavage agent recognition site to the fusion partner. The invention also provides a method of producing a major ampullate spidroin protein and polymers thereof.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: May 20, 2014
    Assignee: Spiber Technologies AB
    Inventors: Jan Johansson, Gäran Hjäm, Margareta Stark, Anna Rising, Stefan Grip, Wilhelm Engsträm, My Hedhammar
  • Publication number: 20140079674
    Abstract: The invention provides an isolated major ampullate spidroin protein, which consists of from 150 to 420 amino acid residues and is defined by the formula REP-CT. REP is a repetitive, N-terminally derived protein fragment having from 80 to 300 amino acid residues. CT is a C-terminally derived protein fragment having from 70 to 120 amino acid residues. The invention further provides an isolated fusion protein consisting of a first protein fragment, which is a major ampullate spidroin protein, and a second protein fragment comprising a fusion partner and a cleavage agent recognition site. The first protein fragment is coupled via said cleavage agent recognition site to the fusion partner. The invention also provides a method of producing a major ampullate spidroin protein and polymers thereof.
    Type: Application
    Filed: November 21, 2013
    Publication date: March 20, 2014
    Applicant: Spiber Technologies AB
    Inventors: Jan JOHANSSON, Goran HJALM, Margareta STARK, Anna RISING, Stefan GRIP, Wilhelm ENGSTROM, My HEDHAMMAR
  • Patent number: 8642734
    Abstract: A method of producing polymers of an isolated spider silk protein involves providing a solution of said spider silk protein in a liquid medium at pH 6.4 or higher and/or an ion composition that prevents polymerization of the spider silk protein. The properties of the liquid medium are adjusted to a pH of 6.3 or lower and an ion composition that allows polymerization of the spider silk protein. The spider silk protein is allowed to form polymers in the liquid medium, and the resulting spider silk protein polymers are isolated from the liquid medium. The resulting polymers are useful as fibers, films, foams, nets or meshes.
    Type: Grant
    Filed: April 21, 2010
    Date of Patent: February 4, 2014
    Assignee: Spiber Technologies AB
    Inventors: Jan Johansson, My Hedhammar, Anna Rising, Kerstin Nordling
  • Patent number: 8618255
    Abstract: The invention provides an isolated major ampullate spidroin protein, which consists of from 150 to 420 amino acid residues and is defined by the formula REP-CT. REP is a repetitive, N-terminally derived protein fragment having from 80 to 300 amino acid residues. CT is a C-terminally derived protein fragment having from 70 to 120 amino acid residues. The invention further provides an isolated fusion protein consisting of a first protein fragment, which is a major ampullate spidroin protein, and a second protein fragment comprising a fusion partner and a cleavage agent recognition site. The first protein fragment is coupled via said cleavage agent recognition site to the fusion partner. The invention also provides a method of producing a major ampullate spidroin protein and polymers thereof.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: December 31, 2013
    Assignee: Spiber Technologies AB
    Inventors: Jan Johansson, Göran Hjäm, Margareta Stark, Anna Rising, Stefan Grip, Wilhelm Engström, My Hedhammar
  • Patent number: 8278416
    Abstract: The invention provides an isolated major ampullate spidroin protein, which consists of from 150 to 420 amino acid residues and is defined by the formula REP-CT. REP is a repetitive, N-terminally derived protein fragment having from 80 to 300 amino acid residues. CT is a C-terminally derived protein fragment having from 70 to 120 amino acid residues. The invention further provides an isolated fusion protein consisting of a first protein fragment, which is a major ampullate spidroin protein, and a second protein fragment comprising a fusion partner and a cleavage agent recognition site. The first protein fragment is coupled via said cleavage agent recognition site to the fusion partner. The invention also provides a method of producing a major ampullate spidroin protein and polymers thereof.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: October 2, 2012
    Assignee: Spiber Technologies AB
    Inventors: Jan Johansson, Göran Hjälm, Margareta Stark, Anna Rising, Stefan Grip, Wilhelm Engström, My Hedhammar
  • Patent number: 8173772
    Abstract: The invention provides an isolated major ampullate spidroin protein, which consists of from 150 to 420 amino acid residues and is defined by the formula KEP-CT. KEP is a repetitive, N-terminally derived protein fragment having from 80 to 300 amino acid residues. CT is a C-terminally derived protein fragment having from 70 to 120 amino acid residues. The invention further provides an isolated fusion protein consisting of a first protein fragment, which is a major ampullate spidroin protein, and a second protein fragment comprising a fusion partner and a cleavage agent recognition site. The first protein fragment is coupled via said cleavage agent recognition site to the fusion partner. The invention also provides a method of producing a major ampullate spidroin protein and polymers thereof.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: May 8, 2012
    Assignee: Spiber Technologies AB
    Inventors: Jan Johansson, Göran Hjälm, Margareta Stark, Anna Rising, Stefan Grip, Wilhelm Engström, My Hedhammar